CureMetrix
Deep learning in medical imaging.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | N/A | Series A | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 35 % | 3 % | 25 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
CureMetrix is a healthcare technology company specializing in artificial intelligence (AI) solutions for breast cancer screening. The company operates in the medical imaging market, providing advanced AI tools to radiologists and healthcare providers. CureMetrix's core products, cmTriage and cmAssist, are designed to improve the accuracy and efficiency of mammogram readings, thereby aiding in the early detection of breast cancer. The company primarily serves hospitals, clinics, and imaging centers that perform mammography. CureMetrix generates revenue through the sale of its AI software solutions, which are typically offered on a subscription basis. The company also engages in partnerships and sponsorships to promote ongoing education and advancements in medical AI. By leveraging FDA-cleared technology, CureMetrix aims to address the backlog of breast cancer screenings exacerbated by the COVID-19 pandemic, ensuring timely and accurate diagnoses.
Keywords: AI, breast cancer, mammography, radiology, healthcare technology, cmTriage, cmAssist, early detection, medical imaging, FDA-cleared.